Trials / Unknown
UnknownNCT03565601
Prognostic Value of Anti-Ro52 Antibodies in Connective Tissue Diseases (a-Ro52)
Phenotypic Features and Prognostic Value of Anti-Ro52 (TRIM-21) Antibodies in Connective Tissue Diseases
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 400 (estimated)
- Sponsor
- Central Hospital, Nancy, France · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Anti-Ro52 autoantibodies can be detected in patients with several autoimmune diseases. Clinical significance of anti-Ro52 is controversial. The presence of anti-Ro52 may be a factor associated with disease severity (interstitial lung disease, vasculopathy) and cancers. The aim of this study is to assess interstitial lung disease and vasculopathy prevalence and severity, cancers occurence and others clinical features of connective tissue disease patients with anti-Ro52 autoantibodies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Follow-up | Clinical data, radiological data and laboratory tests follow-up |
Timeline
- Start date
- 2019-01-01
- Primary completion
- 2020-09-01
- Completion
- 2020-09-01
- First posted
- 2018-06-21
- Last updated
- 2019-12-09
Locations
4 sites across 1 country: France
Source: ClinicalTrials.gov record NCT03565601. Inclusion in this directory is not an endorsement.